论文部分内容阅读
Objective: Treatment options for older pts with R/R ALL are limited.Blinatumomab is a bispecific T-cell engager(BiTE(R)) antibody construct that directs cytotoxic T cells to CD 19-expressing B cells, and is approved in the US for treatment of Ph-R/R ALL.In two phase 2 adult studies of blinatumomab (Topp MS, et al.J Clin Oncol.